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Insulin in motion: The A6-A11 
disulfide bond allosterically 
modulates structural transitions 
required for insulin activity
Bianca van Lierop1, Shee Chee Ong2, Alessia Belgi1, Carlie Delaine2, Sofianos Andrikopoulos3, 
Naomi L. Haworth1,4,5, John G. Menting6, Michael C. Lawrence6,7, Andrea J. Robinson1 & 
Briony E. Forbes  2
The structural transitions required for insulin to activate its receptor and initiate regulation of glucose 
homeostasis are only partly understood. Here, using ring-closing metathesis, we substitute the A6-A11 
disulfide bond of insulin with a rigid, non-reducible dicarba linkage, yielding two distinct stereo-isomers 
(cis and trans). Remarkably, only the cis isomer displays full insulin potency, rapidly lowering blood 
glucose in mice (even under insulin-resistant conditions). It also posseses reduced mitogenic activity 
in vitro. Further biophysical, crystallographic and molecular-dynamics analyses reveal that the A6-A11 
bond configuration directly affects the conformational flexibility of insulin A-chain N-terminal helix, 
dictating insulin’s ability to engage its receptor. We reveal that in native insulin, contraction of the Cα-Cα 
distance of the flexible A6-A11 cystine allows the A-chain N-terminal helix to unwind to a conformation 
that allows receptor engagement. This motion is also permitted in the cis isomer, with its shorter Cα-Cα 
distance, but prevented in the extended trans analogue. These findings thus illuminate for the first 
time the allosteric role of the A6-A11 bond in mediating the transition of the hormone to an active 
conformation, significantly advancing our understanding of insulin action and opening up new avenues 
for the design of improved therapeutic analogues.
Insulin is fundamental to the physiological regulation of blood glucose concentration1. A deficiency in insulin 
results in diabetes, a major economic and primary health care burden across both developed and developing 
countries. Insulin therapy is essential in both type 1 diabetes and late-stage type 2 diabetes, with current ther-
apeutic insulins being designed to restore the normal biphasic insulin response to food intake2,3. While such 
therapeutic analogues are largely successful in controlling blood glucose levels, their means of administration 
and their pharmacokinetic and pharmacodynamic profiles are far from ideal, putting patients at risk of both 
hyper- and hypoglycemia. Notably, none of the currently available therapeutic insulin analogues have employed 
in their design an atomic-level understanding of how insulin engages its receptor, as such detail has only recently 
begun to emerge4,5. A thorough understanding of the conformational changes involved in insulin/insulin receptor 
interaction therefore has the potential to lead to a new generation of insulin analogues with improved pharma-
cological properties.
Insulin is a two-chain polypeptide, comprising an A chain of 21 residues that includes two α helices (residues 
A1 to A8 and A12 to A18, respectively), and a B chain of 30 residues that includes a single α helix (residues B9 to 
B19) (Fig. 1a)6. Integral to insulin’s structure are its three disulfide bonds — one intra-chain (CysA6-CysA11) and 
two inter-chain (CysA7-CysB7 and CysA20-CysB19) (Fig. 1a). Formation of these disulfide linkages ensures both the 
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correct folding of the insulin precursor polypeptide and the structural stability of the mature hormone7,8. Both 
the A6-A11 and the A20-B19 cystines are buried within the core of the hormone, whereas the A7-B7 cystine is 
partly surface exposed. Insulin is stored as a 2Zn hexamer in pancreatic βcells, but it is the monomeric form that 
engages the insulin receptor (a receptor tyrosine kinase)9.
The insulin receptor is a disulfide-linked (αβ)2 homodimer, the ectodomain of which in its apo form adopts a 
folded-over Λ-shaped conformation10,11. Insulin binding to the insulin receptor is currently understood to involve 
the hormone forming a high-affinity cross-link between two distinct sites (1 and 2) on the receptor surface4,12. A 
number of the insulin residues involved in site 1 binding are also involved in forming the insulin dimer within the 
classical 2Zn insulin hexamer (Fig. 1a)4,5,13,14. The location of IR site 2 is not well defined4,10 but evidence exists 
that it is engaged by insulin residues involved in the hexamer-forming surface of the hormone12,14 (Fig. 1a).
Recent crystallographic studies of insulin in complex with domain-minimized insulin receptor constructs 
comprising site 1 alone revealed two key insights into the mechanism of interaction: (i) both the insulin B chain 
and the αCT segment of the receptor undergo conformational change upon their mutual engagement;4,5 in the 
case of insulin, such change involves the long-predicted folding out of the B-chain C-terminal segment (residues 
B24-B30) away from the hormone core15, and (ii) within the complex, the B-chain N-terminal segment does not 
form the N-terminal α-helical extension to the B8-B20 helix that is characteristic of the so-called R- or Rf states of 
the hormone that occur in crystals grown in the presence of phenolic derivatives7, but rather it adopts a confor-
mation similar to that in the classical T-state structures of insulins16, wherein the B-chain N-terminal segment is 
folded back against the hormone7.
Lacking from our current understanding is the role of disulfide bond flexibility in insulin’s engagement with 
the IR. Here, we specifically seek to explore the influence of the A6-A11 disulfide bond on insulin structure and 
function through strategic use of olefin metathesis to replace the A6-A11 disulfide bond of insulin with a C=C 
double bond (Fig. 1b)17. An unsaturated C=C dicarba bond is considerably more rigid than a disulfide bond 
and adopts either a cis or trans configuration, with an insurmountable barrier to exchange under physiological 
conditions. Introduction of a dicarba bond into a number of small polypeptides18 (oxytocin19, calcitonin20, and 
H3-relaxin21) has been shown to improve their stability and, in some cases, their activity. Our synthetic tech-
niques permit generation of both the cis and trans configuration of the A6-A11 dicarba bond within insulin 
(Fig. 1b). Taken together with a re-analysis of extant T-state insulin crystal structures, our structural, molecular 
dynamics and biological characterization of these dicarba insulin isomers leads to a new understanding of the 
critical interplay between A-chain conformational flexibility and restraint that is allosterically regulated by the 
A6-A11 disulfide bond. Such structural transitions are required for insulin/insulin receptor engagement.
Results
Chemical synthesis. While dicarba bonds have been previously introduced into the analogous bond of insu-
lin-like peptides INSL3 and INSL721–23, no strategy exists in the literature to generate A6-A11 intra-chain dicarba 
analogues of human insulin. Here, the highly hydrophobic N-terminus of the insulin A-chain necessitated the 
development of an interrupted solid phase peptide synthesis (SPPS)-catalysis approach24 to overcome deleterious 
aggregation and achieve quantitative ring closing metathesis (see Supplementary Methods). Additionally, to ensure 
exclusive generation of the required C-terminal asparagine residue on resin cleavage, Fmoc-L-Asp-OtBu was 
loaded onto Rink amide resin via its side chain. Microwave-accelerated SPPS in combination with HATU–DIPEA 
activation and Fmoc-protected amino acids were used to generate the truncated peptide sequence 1 (Fig. 2), car-
rying through each intermediate without purification and characterization. Two strategically placed L-allylglycine 
residues were incorporated into the primary sequence to facilitate formation of the intra-chain dicarba bridge, 
and cysteine residues were orthogonally protected to later aid regioselective disulfide oxidation and tethering 
Figure 1. Insulin sequence and structure. (a) Primary sequence (top) of the A (blue) and B (grey) chains of 
human insulin, highlighting disulfide bonds (yellow), site 1-binding residues (underlined) and site 2-binding 
residues (bold)14. Ribbon diagram of insulin (2Zn-coordinated T6 conformation16 PDB entry 1MSO) showing 
the location of the three αhelices and the three disulfide bonds. (b) Schematic diagram of native cystine and 
isomeric cis- and transdicarba bridges.
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of the B chain (Fig. 2). It was critically important to perform the catalysis without the five N-terminal residues; 
performing the ring closure on the full A-chain sequence (21 mer), unlike other insulin-super family molecules, 
gave only poor conversion. Hence, ring-closing metathesis (RCM) of the fully protected, truncated resin-tethered 
peptide 1 (16 mer) was performed in the presence of 20 mol% second-generation Grubb’s catalyst in DCM with 
0.4 M w/v LiCl in DMF.
Under these conditions, microwave irradiation of the peptidyl-resin at 100 °C for 2 h resulted in near quanti-
tative conversion to the desired carbocycle 2. Continued microwave-accelerated SPPS was then performed and 
the remaining five residues (GIVEQ) were appended to the N-terminus to deliver the complete dicarba insulin A 
chain. Mass spectral analysis of the 21-mer gave the required molecular ions for carbocycle 3 and the RP-HPLC 
trace showed the formation of two geometric isomers (E-3 and Z-3) in a 3:1 ratio (see Fig. S1c). Following resin 
cleavage, crude peptide 3 was exposed to an acidic cleavage mixture containing 2,2′-dipyridyl disulfide to facilitate 
concerted tert-butyl-deprotection and pyridinyl-reprotection of residue CysA7. Each of the resultant isomeric 
dicarba insulin peptides 4 were then purified before being subjected to regioselective chain coupling. Construction 
of the complementary insulin B chain 5 was achieved through microwave-accelerated SPPS, in combination with 
HBTU/HOBt–DIPEA activation and Fmoc-protected amino acids, on preloaded Fmoc-Thr(tBu)-PEG-PS resin. 
During chain elongation, orthogonally protected Cys(Trt) and Cys(Acm) residues were strategically incorporated 
into the primary sequence in positions B7 and B19 respectively. Preparative RP-HPLC gave the required insulin B 
chain 5 in 30% yield and 90% purity. The monocyclic A-B conjugates were prepared by combination of the dicarba 
insulin A chains (E-4, Z-4) with the insulin B chain 5 under basic conditions. In all cases, oxidation was complete 
within minutes giving the required 51 amino acid peptides (Fig. 2, E-6 and Z-6). Mass spectral analysis of the iso-
lated solids supported formation of the covalent A-B dimers. The final disulfide bridge in the c[Δ4A6,11]-dicarba 
human insulins (Fig. 2, E-7 and Z-7) was formed on exposure of each of the monocyclic A-B conjugates (E-6, Z-6) 
to iodine under acidic conditions. Removal of the acetamidomethyl (Acm) protecting groups at positions A20 and 
B19 resulted in spontaneous oxidation of the liberated free thiol groups to give the two target isomeric trans- and 
cis-dicarba insulin peptides (Fig. 2, peptides E-7 and Z-7, respectively)17, which were then purified by RP-HPLC 
and independently subjected to biological testing and structural analysis.
Stereochemical assignment of the dicarba bridge. The Cβ chemical shifts of peptides comprising 
Δ4-diaminosuberic acid (Δ4Sub) residues show appreciable differences between the cis-(Z) and trans-(E) con-
figurations25. These features were used to identify the stereochemistry of the insulin A-chain A6-A11 dicarba 
Figure 2. Synthesis of dicarba insulins was performed via ring-closing metathesis (RCM) and an interrupted 
solid phase peptide synthesis (SPPS)-catalysis approach. L-Allylglycine (Agl), tert-butyl (tBu), acetamidomethyl 
(Acm), S-pyridinyl (Pyr), cis isomer (Z), trans isomer (E).
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bridge without the need for structural calculations. Hence, TOCSY and 13C-HSQC spectra were acquired on each 
of the dicarba insulin A-chain peptides (E-4 and Z-4). Δ4Sub Hγ resonances for each E- and Z-dicarba isomer 
were readily identifiable at ~5.6 ppm, which facilitated the assignment of associated Δ4Sub Hβ resonances as well 
as Δ4Sub Cβ resonances in the 13C HSQC. As with other dicarba peptide sequences, only minor differences in 
carbon chemical shifts were observed between the two isomers, with the major difference occurring at the Cβ 
atoms of the dicarba bridge (Fig. S2)25. Consistent with the previously reported model for stereochemical assign-
ment, the upfield Cβ shifts for the cis isomer presented at δ30.9 and δ32.8 and those for the trans isomer appeared 
at δ36.4 and δ36.9. The stereochemistry of the trans isomer E-7 was also confirmed by X-ray crystallography. 
Additionally, an independent, stereoselective synthesis of cis-[A6–11]-dicarba insulin A chain (Z-3) (Fig. SIl) 
was achieved using a preformed, orthogonally protected Z-configured diaminosuberic acid residue (cis-S1)25 and 
SPPS (Fig. S3) and found to be identical to material obtained via RCM (Fig. S1c).
Receptor binding and activation. The affinities of the two dicarba insulin isomers for the human insu-
lin receptor isoforms IR-A and IR-B and the human type 1 insulin-like growth factor receptor (IGF-1R) were 
determined using ligand competition binding assays26. The cis isomer Z-7 was found to bind IR-B and IR-A with 
similar affinity to native insulin, whereas the trans isomer E-7 had a ~50-fold lower affinity for IR-B and IR-A than 
native insulin (Fig. 3a, Table S1 and Fig. S4a). The cis isomer Z-7 bound IGF-1R with similar affinity to insulin 
(Table S1 and Fig. S4c), whereas trans isomer E-7 exhibited negligible affinity to IGF-1R.
In receptor phosphorylation assays, the cis isomer was equipotent to insulin in activation of IR-B (Fig. 3b) and 
IR-A (Fig. S4b), but slightly poorer than insulin in activation of IGF-1R (Fig. S4d), whereas the trans isomer was 
~1000 fold less potent than insulin in activating IR-B (Fig. 3b). The trans isomer had very low binding affinity for 
the IR-A and IGF-1R and its activity at these receptors was left undetermined.
In summary, these data indicate that (i) only one of the two stereochemical isomers of A6-A11 dicarba insulin 
(viz., the cis isomer) is a potent analogue, and (ii) the equipotency of the cis analogue to native insulin is main-
tained despite the increase in rigidity across the A6-A11 connection afforded by the unsaturated dicarba bond.
Metabolic and mitogenic activity. The cis isomer was equipotent to native insulin in promoting glucose 
uptake by NIH3T3-L1 adipocytes (Fig. 3c), aligning with its equipotency in the above receptor binding and recep-
tor activation assays. However, the cis isomer was 5–10 fold less potent than native insulin in promoting DNA 
synthesis, despite its equal affinity for IR and IGF-1R (Fig. 3d). The trans isomer was unable to stimulate DNA 
synthesis significantly above basal levels, correlating with its poor receptor binding ability.
Insulin tolerance test. The cis isomer lowered blood glucose more effectively than native insulin in an 
insulin tolerance test in mice (Fig. 3e,f) measured as described27. This was also evident in insulin-resistant mice 
fed on a high-fat diet (Fig. 3f).
Biophysical characterization. The effect of introduction of a dicarba bond at A6-A11 on protein second-
ary structure and stability was monitored by circular dichroism (CD; Fig. 4). Far UV spectra indicate (Table S2) 
that both the cis- and trans isomers have significantly lower helical content (37% and 23%, respectively) than 
native insulin (48% in our assay, similar to that reported by others28). In our experiments, native insulin exhibits a 
sigmoidal thermal denaturation curve (as monitored by ellipticity at 222 nm) with apparent midpoint Tm = ~60 °C 
(Figs 4a and S5b), similar to the previously-reported value29. In contrast, both dicarba isomers exhibit only a small 
decrease in ellipticity with increasing temperature (Figs 4b and S5c). The slope of the trans isomer denaturation 
curve appears slightly lower than that of the cis isomer, most likely because the trans isomer has a much lower 
initial helical content. Insulin exhibits a two-state transition upon chemical denaturation (ΔG = 4.74 kcal mol−1; 
Fig. 4c). The dicarba insulin analogues are considerably less stable, with inferred ΔG = 1.98 kcal mol−1 for the cis 
isomer and ΔG = 1.6 kcal mol−1 for the trans isomer (Fig. 4c).
Crystal structure determination. The X-ray crystal structures of the cis- and trans isomers were deter-
mined using diffraction data to 2.70 Å and 1.55 Å resolution, respectively, with the crystals being grown under 
similar conditions (see Methods). Data processing and refinement statistics are presented in Table 1. Both crystal 
structures exhibit a T-state-like conformation in that the B chain N-terminal segment adopted an extended con-
formation folded back against the interface between the B chain helix and the polypeptide linker between the two 
A chain helices (Fig. 5a,b). Both crystal structures also contain dimers formed in a fashion closely similar to that 
of the classical insulin T-state dimer. In the crystal structure of the cis isomer, residues A1 to A10 appear largely 
disordered, with the A chain N-terminal helix being represented by no more than a relatively featureless “blob” 
of difference electron density (Fig. 5d). The dimensions of this blob loosely approximate that of the polypeptide 
core of the 8-mer α-helix of the native hormone and likely reflect a crystallographic superposition of the helix 
in a variety of azimuthal and axial orientations. Various unsuccessful attempts were made to obtain alternative 
crystals of the cis isomer with higher structural definition of the A-chain N-terminal helix. Nevertheless, we 
were able to build a tentative model of the cis isomer into the available electron density and to refine this model 
crystallographically to acceptable Rwork/Rfree statistics, though with poor overall stereochemistry (as evidenced 
by the root-mean-square deviations (RMSDs) of the bond angle and bond lengths from ideality; Table 1). The 
Ramachandran plot statistics for the two structures are: trans isomer: 99% in the favoured region, none in the 
disallowed region; cis isomer: 72% in the favoured region, 11% in the disallowed region (the latter values align-
ing with the poor stereochemical nature of the model). We note that, in the trans isomer structure, the A1-A10 
segment is involved in crystal contacts whereas in the cis isomer structure the A1-A10 segment is not involved in 
crystal contacts (or at least not in the putative conformation in which it has been modelled).
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Figure 3. Insulin receptor binding, activation and biological activities of cis- and trans isomers. (a) Competition 
binding of insulin (squares), cis- (triangles) and trans- (circles) isomers with europium-labelled insulin. Results are 
expressed as a percentage of binding in the absence of competing ligand (%B/B0). (b) Activation of IR-B by increasing 
concentrations of dicarba insulins (10 min stimulation) is expressed as receptor phosphorylation as a percentage 
of the maximal phosphorylation induced by insulin. Insulin vs cis isomer (non significant); insulin vs trans isomer 
****(P ≤ 0.0001) (2-way ANOVA; Dunnett’s multiple comparison) (c) Glucose uptake stimulated by increasing 
concentrations of insulin or cis isomer is expressed as fold glucose uptake (pmol/min/mg) above basal. Insulin vs cis 
isomer (ns) (paired T-test). (d) DNA synthesis in response to increasing concentrations of dicarba insulins is shown 
as percentage incorporation of 3H-thymidine (3H-Thy) above basal. All data in (a–d) are the mean ± S.E.M. n = at 
least 3 independent experiments. (e) Insulin tolerance test in mice fed on a normal diet (chow), or (f) on a high fat diet 
were administered through intraperitoneal injection (ip) with 0.75 IU/kg insulin (squares; solid lines) or cis isomer 
(triangles; dotted lines) under non-fasting conditions and tail vein blood glucose was measured via glucose meter at 
indicated times27. n = 5–6 per group. Blood glucose levels are expressed as change over basal levels (mmol/L). Chow 
diet, insulin vs cis isomer ** (P ≤ 0.01); high fat diet, insulin vs cis isomer **(P ≤ 0.01) (paired T-test).
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Structural comparison with native insulin. In order to compare the three-dimensional structure of the 
trans isomer determined here with those of native insulin, we began by analysing the conformations of residues 
A1-A11 in extant insulin crystal structures in the Protein Data Bank (PDB; see Table S3). Inspection of T-state 
structures of (receptor-free) insulin monomers, including monomers from T2, T6, T3R3 and T3Rf3 assemblies 
by alignment of the respective B-chain helices (residues B8-B20) revealed that they could be partitioned into 
two classes on the basis of the conformation of the A-chain N-terminal helix: Class 1 (30 structures), in which 
residues A1 to A9 exhibit the classical (i, i + 4) α-helical hydrogen-bonding pattern; and Class 2 (93 structures), 
wherein residues A1 to A5 form a single α-helical turn and residues A3 to A9 adopt a wider helix conformation, 
approximating an (i, i + 5) π-helix (Fig. 5c,f). The distinction between these two classes is most apparent in the 
hydrogen bonding exhibited by the backbone amide of ThrA8: in Class 1 structures the amide forms a canonical 
α-helical (i, i + 4) hydrogen bond with the backbone carbonyl oxygen of GluA4; however, in the Class 2 structures, 
the amide hydrogen bonds to the backbone carbonyl of ValA3. In many cases, these two classes occur within the 
same crystallographic asymmetric unit structure, with 27 out of 30 Class 1 structures being from crystals that also 
contain within their asymmetric unit an insulin of Class 2 conformation.
Concomitant with these differences in helical conformation are differences in the relative azimuthal posi-
tioning of residues A1-A5 about the helix axis (Fig. 5f and Table S4). In addition, the corresponding mean 
CαA6-to-CαA11 distance of the Class 1 insulins (4.78 ± 0.13 Å) is slightly longer than the mean CαA6-to-CαA11 
distance of the Class 2 insulins (4.55 ± 0.37 Å). Concomitantly, the mean CαA7-to-CαB7 distance of the Class 
1 insulins (4.62 ± 0.12 Å) is slightly shorter than the mean CαA7-to-CαB7 distance of the Class 2 insulins 
(4.76 ± 0.11 Å) (Table S5).
The crystal structure of the trans isomer corresponds to a Class 1 insulin conformation. Residues A1-A9 
exhibit a classical α-helical geometry, with the azimuthal positioning of residues A1-A5 being closely similar 
to that of native insulins within Class 1 (Fig. 6a). In addition, the CαA6-to-CαA11 distance (5.17 Å) in the trans 
isomer is more similar to the corresponding average CαA6-to-CαA11 distance of the Class 1 insulins than the 
average CαA6-to-CαA11 distance of the Class 2 and IR-bound native insulin (PDB entries 4OGA, 3W12, 3W13) 
(Table S5).
Our analyses are consistent with the report of Kaarlsholm et al.30 of two forms of insulin that differ at residues 
A1-A5 through a rotation of 32° about the CysA6 Cα-NH bond in the crystal structure of 2Zn porcine insulin16. 
The Class 2 conformation of the A chain N-terminal helix is also observed in insulin analogues synthetically engi-
neered to reposition the B chain C-terminal segment away from the hormone core, e.g. des[23–30]-insulin (PDB 
Figure 4. Thermal and chemical stability of cis- and trans isomers. (a) Circular dichroism far-UV spectra reveal 
lower helical propensities in both the cis- and trans isomers. θ = ellipticity. (b) Differences in thermal unfolding 
are monitored by ellipticity at 222 nm and show both the cis- and trans isomers are considerably less stable than 
insulin. (c) Unfolding in the presence of guanidine demonstrates that both isomers are considerably destabilized 
compared to insulin. ΔG values derived from guanidine denaturation studies are listed.
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1DEI)31 and NMeAla-B26-DTI insulin analogue (PDB 2WRX)32. Our study is, however, the first to recognize 
the allosteric role played by the A6-A11 disulfide bond in this conformational switch without movement of the B 
chain C-terminal segment.
As far as we can ascertain from the structures of the insulin/IR Site 1-complexes (PDB entries 4OGA, 
3W12 and 3W13, at resolution (3.5–3.9 Å)), the A-chain N-terminal helix of insulin (and insulin analogues) 
exhibits a Class 2-like structure when bound to IR (see Fig. 6). This is apparent in the larger-diameter A-chain 
N-terminal helix and shorter CαA6-to-CαA11 distance than those observed for Class 1 insulins, and in a similar 
azimuthal positioning of the constituent Cα atoms to those within Class 2 structures. The ability of the insulin 
A-chain N-terminal helix to adopt these two classes of structure indicates both (i) a degree of conformational 
flexibility in the three covalent bonds that connect that helix to the remainder of the hormone (viz., the A6-A11 
and A7-B7 disulfide bonds and the downstream peptide bond), and (ii) rotameric plasticity of the side chains of 
the residues that form the interface between that helix and the remainder of the hormone (Fig. 5c,f).
Molecular dynamics simulations. Molecular dynamics (MD) simulations were conducted to explore the 
significance of conformational flexibility in the A6-A11 linkage and the A1-A9 helix — in particular, the distinc-
tion between the Class 1 and Class 2 conformations. Three high-resolution X-ray crystal structures were selected, 
each having a different conformation of the A6-A11 disulfide linkage (PDB entry 1G7B chains E and F, Class 
2; PDB entry 1MSO chains A and B, Class 1; and PDB entry 3I3Z chains A and B, Class 2). Each structure was 
also modified to contain cis and trans isomers, resulting in nine starting structures. Multiple 200 ns MD simu-
lations were then conducted based on each starting structure. In all simulations, it was evident that the A-chain 
N-terminal helix was highly mobile and, in many cases, interchange between classes was also observed. Indeed, 
although each starting structure belonged initially to a particular Class, that distinction appeared not to survive 
the pre-optimization phase, and hence did not bias the simulations.
Root mean square deviations (RMSDs) with respect to a representative Class 2 structure were calculated for 
all atoms of residues A1 to A4 for each frame of each MD simulation. From the RMSD plots (Fig. 5g–i), it is 
seen that both insulin and the cis isomer can approach the Class 2 conformation (RMSD < ~1.5 Å), albeit rarely 
(Fig. 5g,i). In contrast, the trans isomer almost never adopted a Class 2 conformation, with RMSD values being 
generally > 2 Å and very rarely < 1.5 Å (two disparate frames out of 12,000 had an RMSD < 1.5 Å) (Fig. 5h). 
Interestingly, three different hydrogen-bonding partners for the backbone amide of ThrA8 were observed in the 
structures generated in the MD simulations: ValA3 (i, i + 5; π-helix), GluA4 (i, i + 4; α-helix) and GlnA5 (i, i + 3; 
310-helix) (Table S6). For both insulin and the two dicarba isomers, GluA4 and GlnA5 were the dominant hydro-
gen bonding partners. A backbone hydrogen bond between ThrA8 and ValA3 was seen only in ~4% of simulation 
frames for insulin and the cis isomer and never in any of the trans isomer MD runs. Cluster analysis suggests 
cis isomer trans isomer
Data collection1
  Space group I213 P213
  Cell dimensions a, b, c (Å) 79.78, 79.78, 79.78 77.28, 77.28, 77.28
  Resolution (Å) 28.20–2.70 (2.80–2.70)2 30–1.55 (1.60–1.55)2
  Rmerge 0.066 (1.653) 0.144 (5.03)
  I/σ (I) 16.19 (1.13) 11.72 (0.38)
  CC1/2 0.999 (0.280) 0.999 (0.107)
  Completeness (%) 98.8 (98.9) 0.999 (1.00)
  Redundancy 6.0 (6.2) 10.8 (10.4)
  Molecules/asymmetric unit 1 2
Refinement
  Resolution (Å) 28.20–2.70 30.0–1.55







    Protein (Å2) 120. 33.4
    Water n.a. 46.7
R.m.s. deviations
    Bond lengths (Å) 0.011 0.006
    Bond angles (°) 1.5 0.8
Table 1. X-ray diffraction data processing and refinement statistics. 1Diffraction data are from a single crystal 
in both instances. 2Resolution limits were set based on the CC1/2 correlation statistic being assessed significant at 
the P = 0.001 level of probability. 3Free set comprised 5% of the reflections.
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that structures with ThrA8-GluA4 and ThrA8-GlnA5 backbone hydrogen bonds are not distinct conformations and 
transitions between them are part of a natural “breathing” mode of the helix, possibly explaining why ThrA8-GlnA5 
backbone hydrogen bonds have not been found in extant crystal structures. The average CαA6-to-CαA11 distance 
for Class 1 insulin and for cis isomer structures were effectively the same within the MD trajectories and the 
X-ray structures (Table S5). Curiously, the average CαA6-to-CαA11 distances for Class 2 structures in the MD 
simulations (4.05 Å and 3.97 Å for the cis isomer and insulin, respectively) were found to be shorter than seen in 
the crystal structures (4.50 Å and 4.55 Å for the cis isomer and insulin, respectively), suggesting that the distance 
is possibly distorted from its optimal value in the crystalline phase, or that there are differences in the respective 
stereochemical libraries that underpin MD and crystallographic refinement methodologies.
It is important to note that the variations in the RMSDs through the time course of the simulations (Fig. 5g–i) 
are larger for the cis isomer (σ = 1.3 Å) than for either the trans isomer (σ = 1.0 Å) or insulin itself (σ = 0.9 Å). 
Figure 5. Structural comparison of cis- and trans isomers with T-state insulin structures. (a) The cis- and (b) 
trans isomers represent T-state insulins with conserved B-chain structures (cyan). The cis isomer has a poorly 
defined A1-A8 helix (dotted line), whereas the two trans isomers in the crystallographic asymmetric unit both 
display a Class 1 A1-A8 helix. (c) The two insulin structures within the asymmetric unit of PDB entry 1MSO 
aligned across their B chain helices, showing both a Class 1 (light blue) and Class 2 (dark blue) A1-A8 helix. 
(d) (2mFobs − DFcalc) difference electron density associated with the residues within the N- and C-terminal 
helices of the A chain of the cis isomer; contour level: 1 σ. (e) (2mFobs − DFcalc) difference electron density in 
the vicinity of the A6-A11 dicarba bond (arrowed) within the trans isomer, contour level: 1.3 σ. (f) A zoom-in 
view of the boxed selection in panel (c) highlighting the differences in the A2, A3 and A4 side-chain positions 
of the two different classes. Analysis of molecular dynamics data of (g) cis isomer (h) trans isomer and (i) 
insulin, showing RMSDs of all atoms of residues GlyA1 to GluA4 for each simulation frame with respect to a 
representative Class 2 conformation structure (referred to as T-wide here). Regions corresponding to the Class 
2 conformation are shaded yellow. Average RMSDs over all simulation frames for insulin, cis isomer and trans 
isomer are 3.0 ± 0.9 Å, 3.4 ± 1.3 Å and 3.5 ± 1.0 Å, respectively. Note that each bin between pairs of tick marks 
on the horizontal axis represents a separate 200 ns simulation.
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This indicates that the N-terminus of the cis isomer is more conformationally flexible than that of the other ana-
logues, suggesting an explanation for the disorder of this helix in the X-ray crystallographic maps. Although the 
cis isomer is seen to access the Class 2 conformation in MD simulations and the trans isomer is not, their average 
RMSDs from the Class 2 conformation across all simulation frames are similar (3.4 and 3.5 Å, respectively) and 
are higher than for insulin (3.0 Å). These increased RMSDs for the dicarba insulin analogues correlate with sta-
tistically significant decreases in the helicity of the N-terminal A chain residues (as measured by the backbone 
conformations of the relevant resides) in comparison with that of insulin (see Table S7).
Discussion
Whereas the role of individual insulin surface residues in receptor binding has been intensively investigated, there 
has been less examination of the physico-chemical nature of the disulfide bonds, their stereochemistry, and their 
structural contribution to insulin/IR engagement and resultant biological activities. Here, we have synthesized 
the two stereoisomers of an A6-A11 dicarba insulin, determined their crystal structures and characterized their 
biochemical and biophysical nature. Ruthenium-alkylidene catalyzed ring-closing metathesis of insulin A-chain 
sequences bearing a pair of allylglycine residues provided an expedient route to intra-chain dicarba insulin ana-
logues with different stereochemical configurations.
The dicarba stereoisomers exhibit two intriguing biological characteristics. First, the cis isomer is active and 
the trans inactive, as evidenced in in vitro assays (receptor binding, receptor activation and glucose uptake by adi-
pocytes). The cis isomer also demonstrates promising therapeutic potential, evident from its ability to lower blood 
glucose more rapidly than native insulin in both normal and insulin-resistant mice. Second, the cis isomer is sig-
nificantly less potent than native insulin in stimulating DNA synthesis, indicating its reduced ability to promote 
cell growth/replication. The unique biological characteristics of the dicarba stereo-isomers reflect the structural 
outcomes of the respective rigid configurations of the dicarba linkages. These findings thus presented us with an 
opportunity to utilize the stereoisomers as tools to scrutinize further the mechanistic role of A6-A11 bond and its 
influence in mediating the structural transitions of insulin to its active conformation.
To this end we sought to identify structural features that might account for the differences in biological activi-
ties of the cis and trans isomers. Intriguingly, both isomers exhibit reduced helical content as assessed by CD and 
by MD. In the case of the cis isomer, such reduced helical content in solution is consistent with the disorder of the 
A-chain N-terminal helix observed in its crystal structure. In the case of the trans isomer, CD measurement indi-
cates a lower helical content than the cis isomer. However, both molecules within the crystallographic asymmetric 
unit of the trans isomer show an ordered A chain N-terminal helix. Unlike in the structure of the cis isomer, the 
respective A-chain N-terminal helices of the two trans isomers are involved in crystal contacts, suggesting their 
crystallographic order may be brought about by these contacts: in solution, the trans isomer A chain is likely 
disordered. In support, our preliminary atomic force microscopy analysis (to be published elsewhere) shows an 
increased rate of fibrillation of both dicarba isomers compared to that of insulin. A key feature of fibril formation 
is proposed to be loss of helical structure as the A-chain N-terminal helix transitions to a β sheet33. Consistent 
with our CD and MD data, earlier studies show that the A-chain N-terminal helix is susceptible to perturbation 
through removal of the A6-A11 disulfide bond29,34,35 or residue substitution elsewhere within the helix36–39 and 
that it can undergo conformational fluctuation36,40.
An explanation for the cis isomer being active and the trans isomer being inactive arises from our analysis of 
extant T-state insulin structures. The existence of the two Classes (1 and 2) of T-state insulin structures suggests 
that the hormone is capable of transition between the two forms. As far as can be ascertained at the resolution of 
the IR-site-1-complexed structures of insulin, the IR-bound conformation of the hormone corresponds to Class 
Figure 6. Structural comparison of the trans isomer with native insulin in its IR site-1 bound and receptor-free 
forms. (a) Overlay of trans isomer (pink/cyan) with T6 insulin (PDB entry 1MSO, Class 1 (light blue/grey),  
Class 2 (dark blue/grey)) and with IR site-1 bound insulin (PDB entry 4OGA, gold/grey). Differences in the 
A2, A3 and A4 side-chain positions arise through rotation of the A1-A8 helix. In the complex this allows 
accommodation of the IR αCT (not shown). (b) In the IR site-1 bound conformation, insulin’s A1-A8 helix 
adopts a Class 2 conformation and the A2-A4 residues rotate to enable engagement with IR αCT (dark green), 
with insulin A3 and A4 residues flanking Asn711 of IR αCT. This conformation and rotation does not occur in 
trans isomer. Colors are otherwise as in (a).
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2. The crystal structure of the trans isomer indicates that it has a Class 1 conformation, and its inactivity suggests 
that it is incapable of transitioning to a Class 2 structure. This hypothesis is supported by the MD simulations, 
which show that, although the trans isomer is capable of transiently adopting a range of structures, the Class 2 
conformation appears to be precluded. An overlay of trans isomer and Class 1 insulin X-ray structures onto those 
of Class 2 and receptor-bound (PDB entry 4OGA) insulins shows a distinction between the two sets of structures 
(Fig. 6a), with the N-terminal end of the helix axis adopting different rotational configurations with respect to the 
hormone core (highlighted in Supplementary Information Movie 1). The overlay also indicates that there would 
be a significant steric clash between side chain of GluA4 of the Class 1/trans isomer structures and the side chains 
of Asn711 within the receptor αCT helix (Fig. 6b).
Hence, introduction of the cis and trans dicarba linkages is seen to affect the structural dynamics of the A 
chain N-terminal helix in three ways: (i) increased short-range motion: both cis and trans linkages disrupt the res-
idue backbone conformations (i.e., helicity), as evidenced in both the CD spectroscopy and the MD simulations—
this possibly due to the increased rigidity of the dicarba linkages transmitting more vibrational energy from 
the rest of the molecule into the helix in comparison with the less rigid disulfide bond of insulin; (ii) increased 
long-range motion in the cis isomer, evidenced by the increased range of RMSDs (Fig. 5g) and the corresponding 
increased standard deviation seen in the MD simulations, as well as in the disorder apparent in the cis isomer 
X-ray structure; and (iii) decreased conformational flexibility in the trans isomer: the longer trans-dicarba bond 
(Table S5) changes the conformation of the A6-A11 loop, preventing the formation of a ThrA8-ValA3 hydrogen 
bond and hence the adoption of a Class 2 conformation. The inability of the trans isomer to adopt a Class 2 con-
formation (as seen within the MD simulations) then precludes its engagement with IR site 1 and results in its 
observed biological inactivity.
The activity of the cis isomer demonstrates that reduction-oxidation of the native A6-A11 disulfide bond 
(if it occurs) does not play an obligatory role in IR binding and activation. Rather, we suggest that the A6-A11 
disulfide bond is able to modulate the insulin conformation through allostery, key elements of which are revealed 
by our study. The ability of the A6-A11 cystine bridge to adopt a range of disulfide conformations (Table S3) 
allows switching of the N-terminal region of the insulin A chain between active (Class 2) and inactive (Class 1) 
conformations. The active conformation requires a short A6-A11 Cα-Cα distance and a concomitant lengthening 
of the distance between the Cα atoms of A7 and B7 (Table S5). The short A6-A11 Cα-Cα distance of the Class 
2 structures appears to result in a “pulling” of the N-terminal end of A1-A8 helix away from the volume that 
would be occupied by IR αCT in a putative receptor complex (a conformation also adopted by mutation of B26 to 
NMeAla or NMeTyr32). In contrast, the longer A6-A11 linkage seen in Class 1 structures results in the base of the 
A chain N-terminal helix being closer to the B chain as a direct consequence of the A7-B7 disulfide bond length 
(Table S5). Critically, the short A6-A11 Cα-Cα distance seen in the active Class 2 conformations appears to be 
necessary to allow a precise rotation of the A-chain N-terminal helix, which in turn positions the side chains of 
residues A2 to A4 in an orientation compatible with receptor binding. In insulin, it is the adoption of a particular 
A6-A11 disulfide conformation that gives the required Cα-Cα distance and hence access to the active confor-
mation. While both cis and trans A6-A11 dicarba bonds promote flexibility in the A1-A8 helix, it is only the cis 
dicarba linkage that can allow the A6 and A11 Cα atoms to come into the close proximity required to adopt a 
Class 2 structure. The increased interchain length resulting from the presence of a trans carbon-carbon double 
bond means that the active conformation is not accessible to the trans isomer.
Conclusions and Outlook
Through detailed analysis of the structure and function of the two dicarba insulin isomers generated through 
novel chemistry, our investigation provides the first description of the key role that the evolutionarily-conserved 
A6-A11 cystine bridge plays as an allosteric switch of insulin activity. We reveal that both the configuration and 
flexibility of the A6-A11 disulfide linkage are essential elements in insulin’s adoption of an active conformation. 
Additionally, we conclude that the A6-A11 dicarba linkage of the cis isomer can also adopt a configuration that 
enables insulin receptor binding. This leads to effective lowering of blood glucose levels in mice and a signifi-
cantly reduced ability to promote mitogenic signaling, a highly desirable biological property. Thus, the cis isomer 
represents an analogue with promising clinical potential. In conclusion, we have revealed a novel mechanism 
underlying insulin receptor engagement that dictates downstream biological outcomes. Using these findings as a 
basis we can now design improved insulin analogues for the treatment of diabetes.
Methods
Materials. Actrapid Insulin was purchased from Lyppard Australia Pty Ltd. Hybridoma cells expressing anti-
bodies specific for the IR α subunit (83-7) and the IGF-1R α subunit (24–31) were a gift from Prof. K Siddle41–43. 
[3H]-Thymidine was purchased from PerkinElmer Life Sciences. hIR-A and hIR-B overexpressing R-fibroblast 
cells (derived from IGF-1R knockout mouse embryonic fibroblasts, a gift from Prof. R. Baserga (Philadelphia, 
USA)44, were produced according to Denley et al.26 hIR-A over-expressing L6 myoblasts were provided by Dr. 
B.F. Hansen (Novo Nordisk A/S, Denmark). P6 cells (BALB/c3T3 cells overexpressing the human IGF-1R) were 
from Prof. R. Baserga45.
Synthesis of dicarba insulins. An interrupted solid-phase peptide synthesis (SPPS)-catalysis 
approach24 was developed to overcome deleterious aggregation and achieve quantitative ring-closing metath-
esis of the dicarba insulin A chain. Construction of the complementary insulin B chain was achieved through 
microwave-accelerated SPPS. The monocyclic A-B conjugates were prepared by combination of the dicarba insu-
lin A chains with the insulin B chain under basic conditions resulting in spontaneous oxidation of the liberated 
free thiol groups to give the two target isomeric trans and cis dicarba peptides. The details of this method are 
provided in the Supplementary Methods.
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Receptor competition binding assays and kinase receptor activation assays (KIRA). Human IR-A, 
IR-B and IGF-1R binding affinities and receptor phosphorylation were measured as described by Denley et al.26  
Assays were performed in triplicate in at least three independent experiments.
DNA synthesis assay. DNA synthesis was carried out as described in Gaugin et al.46. Briefly, L6 rat skeletal 
myoblasts overexpressing human IR-A, were plated in a 96-well flat bottom plate (1.5 × 104 cells/well) and grown 
overnight at 37 °C, 5% CO2. Cells were starved in serum-free medium for 4 h before treatment with increasing 
ligand concentrations for 18 h in Dulbecco’s minimal essential medium with 1% bovine serum albumin. The cells 
were incubated with 0.13 μCi/well [3H]-thymidine for 4 h, shaken for 2 h with 50 μL disrupting buffer (40 mM Tris 
pH 7.5/10 mM EDTA/150 mM NaCl) and then harvested onto glass fibre filters (Millipore®) using a MICRO 96TM 
Skatron harvester (Molecular Devices). The filters were counted in a Wallac MicroBeta counter (PerkinElmer Life 
Sciences). Assays were performed in triplicate in at least three independent experiments.
Glucose uptake assay. Briefly, NIH3T3-L1 myoblasts (up to passage 20) grown in DMEM supplemented 
with 10% newborn calf serum, 2 mM L-glutamine, 100 U/l penicillin, 100 μg/L streptomycin at 37 °C were seeded 
into 24-well plates at 5 × 103 cells/well and grown for 8 days to confluence and were then differentiated into 
adipocytes as described47. Glucose uptake in response to insulin and the cis isomer was measured essentially 
as described48. Briefly, 3T3-L1 adipocytes were serum starved in serum free DMEM/1% BSA for 4 h, washed 
twice with Krebs-Ringer phosphate buffer (KRP, 12.5 mM HEPES, 120 mM NaCl, 6 mM KCl, 1.2 mM MgSO4, 
1 mM CaCl2, 0.4 mM Na2HPO4, 0.6 mM Na2HPO4 (pH 7.4)) containing 1%BSA and incubated for 15 min at 
37 °C. Insulin or the cis isomer was added at decreasing concentrations (100-0.3 nM) for 30 min at 37 °C. For the 
final 10 min, 2-deoxyglucose (DOG) uptake was initiated by the addition of 50 μM cold deoxyglucose and 1 μCi 
3H-deoxyglucose per well. The assay was terminated by rapidly washing the cells three times with ice-cold KRP 
buffer. Cells were solubilized in 0.5 M NaOH/0.1% SDS and 3H content was determined by scintillation counting. 
Nonspecific 2-DOG uptake was determined in the presence of 50 μM cytochalasin B.
Insulin tolerance test. Eight-week-old C57BL6 male mice were fed either a standard rodent chow diet 
containing (wt/wt) 77% carbohydrate, 20% protein, and 3% fat from Ridley AgriProducts (Pakenham, Victoria, 
Australia) or a high fat diet (HFD) containing (wt/wt) 57% carbohydrate, 19% protein and 15% fat from Specialty 
Feeds (SF08-044, Glen Forrest, Western Australia, Australia) for 12 weeks. Mice (5 or 6 mice per group) were 
injected ip with 0.75I U/kg insulin or cis isomer under non-fasting conditions and tail vein blood glucose was 
measured via glucometer at indicated times27. Experimental procedures were carried out in accordance to the 
protocols approved by the Austin Health Animal Ethics Committee (AEC 2011/04396).
Circular Dichroism (CD). CD was carried out as previously described29,49. Briefly, CD spectra were recorded 
on a Jasco J-815 CD spectrometer; spectra were from 260 to 190 nm with a 1.0 nm step size using a 1.0 s response 
time and 1.0 nm bandwidth in a quartz cuvette with a 0.1 cm path length. Insulin and dicarba insulin analogues 
were diluted in 10 mM phosphate buffer (pH 7.4) to a concentration of 0.22 mg/mL (38 μM). Spectra were 
background-corrected by subtraction of the spectrum of buffer alone. Temperature denaturation was achieved 
by automated thermal control increasing by 2°/min at 1° intervals. Samples were diluted to 10 μM for equilibrium 
denaturation studies in guanidine hydrochloride (1.0–8.0 M).
Bioinformatics. A dataset of insulin structures was constructed from all medium- and high-resolution X-ray 
crystal structures (better than 2.8 Å) in PDB Archive Version 4.0 (Jul 2011). 275 unique insulin structures were 
found in 105 PDB files; these included human, bovine and porcine insulins and synthetic mutants. 152 structures 
were found to exhibit the R (or Rf) state (data not shown) and 123 the T state. (Note: structures with A6-A11 
Sγ-Sγ bond lengths outside the range of 1.95 to 2.05 Å (indicative of poor modelling of the disulfide), as well as 
structures involving insulin in complex with the insulin degrading enzyme, were not included in the dataset.) 
Analyses were performed only on T-state insulins (i.e., T-state insulins from monomeric, T2, T6, T3R3 or T3Rf3 
structures). Of the T-state structures, 30 exhibited a Class 1 conformation and 93 a Class 2 conformation. Custom 
programs were used to extract the CαA6-to-CαA11 and CαA7-to-CαB7 distances and A6-A11 disulfide conforma-
tions, as well as the hydrogen bonding pairs, from each structure (see Supplementary Information). The approach 
used to determine the relative azimuthal positioning of residues within the segment A1-A10 of each insulin is also 
described in the Supplementary Information.
Molecular Dynamics (MD). Molecular dynamics simulations were performed using the AMBER14 program 
package50. Amber ff14SB force field parameters51 were used for all standard amino acid residues. RESP charges52 and 
force-field parameters for the dicarba linkages were determined using the PyRED program53,54 (see Supplementary 
Information). Initial atomic coordinates were taken from three high-resolution T-state insulin PDB entries: 1G7B 
E,F; 1MSO A,B; and 3I3Z A,B. Each of these structures has a different conformation for the A6-A11 disulfide 
bond. Cis and trans isomers were created from each entry, giving a total of nine different starting structures. After 
minimization and equilibration (see Supplementary Information), the system was heated to 400 K and the dynamics 
simulated for 10 ns. Each high-temperature simulation was analysed to identify distinct conformations of the insu-
lin analogue. Four structures (or 8 in the case of the cis isomer, see Supplementary Information) were chosen from 
each run to use as starting geometries for subsequent 200 ns room-temperature MD simulations. Full details of 
simulation protocols are provided in the Supplementary Information. Processing of simulations and cluster analysis 
was performed using CPPTRAJ55. The same custom programs as described above under Bioinformatics were used 
to assess the backbone hydrogen-bonding patterns, interatomic distances and A6-A11 disulfide conformations in 
each MD simulation frame. DSSP56 was also used to identify residue backbone conformations.
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Crystallization. trans isomer: An initial sparse-matrix sitting-drop vapor-diffusion crystallization screen was 
conducted at the CSIRO Collaborative Crystallisation Centre (CSIRO C3; Parkville, Australia). Based on hit con-
ditions determined, a ca 50 μm crystal was then grown at 20 °C in a 24-well Linbro plate by vapor diffusion from 
a hanging drop of 1 μL of 1 mg/ml protein dissolved in 10 mM HCl mixed with 2 μL crystallant solution (0.9 M 
potassium sodium tartrate, 0.1 M Tris HCl (pH 8.5), 0.5% PEG 5000 MME) on a siliconized coverslip (Hampton 
Research) placed over 0.4 mL crystallant. The crystal was placed in a second hanging drop vapor diffusion con-
dition, a 2 μL drop of 1.0 M potassium sodium tartrate, 0.1 M Tris HCl pH 8.5 and equilibrated against 0.4 mL 
of 1.5 M potassium sodium tartrate overnight at 20 °C, after which the well solution was exchanged for saturated 
potassium sodium tartrate and incubated for 24 h. The crystal was cryo-cooled by direct plunging into liquid 
nitrogen (without addition of a cryo-stabilizing solution). cis isomer: Following an initial sparse-matrix screen 
identical to that described above for the trans isomer, a ca 25 μm crystal was subsequently grown at CSIRO C3 in 
a 96-well additive screen using a SWISSCI plate in vapor diffusion format at 20 °C using a sitting drop of 150 nL 
of 1 mg/ml protein dissolved in 10 mM HCl mixed with 150 nL 0.8 M potassium sodium tartrate, 0.1 M Tris-HCl 
pH 8.5, 0.5% PEG 5000 MME, 4% acetonitrile. This crystal was briefly dipped in paraffin oil (Hampton Research) 
and cryo-cooled by direct plunging into liquid nitrogen.
Diffraction data collection and processing. Diffraction data for both crystals were collected at the MX2 
beamline at Australian Synchrotron57 at ~100 K and at λ = 0.9537 Å. Diffraction data were processed and merged 
using XDS58; statistics are presented in Table 1.
Crystallographic structure solution and refinement. Molecular replacement solutions for both iso-
mers were obtained using PHASER59, with the starting model in both cases being a porcine insulin monomer 
obtained from PDB entry 1B2A60. Structure refinement was performed with PHENIX59 iterated with manual 
model building within COOT61. In the case of the cis isomer, the density remained exceptionally poor for the A 
chain N-terminal helix and for residues in vicinity of the dicarba bond. Attempts were made to refine the struc-
ture as an ensemble62, but without success. Final refinement statistics are presented in Table 1.
Statistical Analyses. Statistical analysis of receptor binding, receptor activation and DNA synthesis assays 
were performed using a 2-way ANOVA with a Dunnett’s multiple comparison. Insulin tolerance test and glucose 
uptake assay data were analysed with a paired T-test. Significance was accepted at P < 0.05.
Data Availability Statement. All data generated or analyzed during this study are included in this pub-
lished article (and its Supplementary Information files). Protein Data Bank (PDB) coordinates for the crystal struc-
ture of trans isomer have been deposited with accession code PDB 5T7R. The model coordinates and associated 
crystallographic structure factors of the cis isomer are included as cis_isomer.cif; the unreliability of the model 
precludes deposition in the PDB.
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